OBJECTIVE: To observe the efficacy and safety of albumin-bound paclitaxel (ABP) monotherapy in treating recurrent advanced non-small-cell lung cancer (NSCLC). METHODS: We retrospectively analyzed the short-term efficacy and toxicities of ABP monotherapy in treating 21 patients who had previously undergone multiple cycles of therapy for their advanced NSCLC in our hospital since 2010. The treatment-related survival was also analyzed. RESULTS: Of these 21 patients, the best overall response was partial response (PR) in 6 patients (28.6%), stable disease (SD) in 10 patients (47.6%), and progressive disease (PD) in 5 patients (23.8%). The overall response rate (ORR) was 28.6% and the disease control rate (DCR) (PR + SD) was 76.2%. The median progression-free survival (PFS) was 4.0 months (95% CI, 5.0-7.0 months). The main grade 3/4 toxicities included neutropenia (11.1%), peripheral nerve toxicity (5.6%), muscle and joint aches (5.6%), and fatigue (5.6%). CONCLUSIONS: The ABP monotherapy can achieve good objective response in advanced NSCLC patients who have previously received multiple cycles of treatment and be well tolerated.
OBJECTIVE: To observe the efficacy and safety of albumin-bound paclitaxel (ABP) monotherapy in treating recurrent advanced non-small-cell lung cancer (NSCLC). METHODS: We retrospectively analyzed the short-term efficacy and toxicities of ABP monotherapy in treating 21 patients who had previously undergone multiple cycles of therapy for their advanced NSCLC in our hospital since 2010. The treatment-related survival was also analyzed. RESULTS: Of these 21 patients, the best overall response was partial response (PR) in 6 patients (28.6%), stable disease (SD) in 10 patients (47.6%), and progressive disease (PD) in 5 patients (23.8%). The overall response rate (ORR) was 28.6% and the disease control rate (DCR) (PR + SD) was 76.2%. The median progression-free survival (PFS) was 4.0 months (95% CI, 5.0-7.0 months). The main grade 3/4 toxicities included neutropenia (11.1%), peripheral nerve toxicity (5.6%), muscle and joint aches (5.6%), and fatigue (5.6%). CONCLUSIONS: The ABP monotherapy can achieve good objective response in advanced NSCLCpatients who have previously received multiple cycles of treatment and be well tolerated.
Authors: F V Fossella; R DeVore; R N Kerr; J Crawford; R R Natale; F Dunphy; L Kalman; V Miller; J S Lee; M Moore; D Gandara; D Karp; E Vokes; M Kris; Y Kim; F Gamza; L Hammershaimb Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544
Authors: F A Shepherd; J Dancey; R Ramlau; K Mattson; R Gralla; M O'Rourke; N Levitan; L Gressot; M Vincent; R Burkes; S Coughlin; Y Kim; J Berille Journal: J Clin Oncol Date: 2000-05 Impact factor: 44.544
Authors: David F Heigener; Yi-Long Wu; Nico van Zandwijk; Pekka Mali; Keith Horwood; Martin Reck Journal: Lung Cancer Date: 2011-03-24 Impact factor: 5.705
Authors: Craig Reynolds; David Barrera; Robert Jotte; Alexander I Spira; Charles Weissman; Kristi A Boehm; Sharon Pritchard; Lina Asmar Journal: J Thorac Oncol Date: 2009-12 Impact factor: 15.609
Authors: Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn Journal: J Clin Oncol Date: 2004-05-01 Impact factor: 44.544
Authors: Naiyer A Rizvi; Gregory J Riely; Christopher G Azzoli; Vincent A Miller; Kenneth K Ng; John Fiore; Gloria Chia; Martin Brower; Robert Heelan; Michael J Hawkins; Mark G Kris Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544
Authors: Thomas E Stinchcombe; Mark A Socinski; Carrie B Lee; D Neil Hayes; Dominic T Moore; Richard M Goldberg; E Claire Dees Journal: J Thorac Oncol Date: 2008-05 Impact factor: 15.609
Authors: Eric P Winer; Donald A Berry; Susan Woolf; David Duggan; Alice Kornblith; Lyndsay N Harris; Richard A Michaelson; Jeffrey A Kirshner; Gini F Fleming; Michael C Perry; Mark L Graham; Stewart A Sharp; Roger Keresztes; I Craig Henderson; Clifford Hudis; Hyman Muss; Larry Norton Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: Ashish Saxena; Bryan J Schneider; Paul J Christos; Lauren F Audibert; Jennifer M Cagney; Ronald J Scheff Journal: Med Oncol Date: 2016-01-09 Impact factor: 3.064